Advertisements

Depovit B12

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Depovit B12

Quick Facts: Depovit B12 Identity

Property Description
Active Ingredient Cyanocobalamin (Vitamin B12)
Form Solution for injection (Ampoules)
Pharmacological Class Antianemic, Haemopoietic Agent
Common Purpose Addressing B12 deficiency
Origin Synthetic derivative

What Type of Medicine is Depovit B12?

Depovit B12 is a prescription-only cobalamin preparation that is clinically recognized as an antianemic and haemopoietic agent, meaning it supports the essential process of producing healthy blood cells. It belongs to the class of water-soluble vitamins and is primarily used when there is a confirmed inability to absorb Vitamin B12 effectively through the digestive tract. The active component is Cyanocobalamin, which is utilized to address deficiency and promote red blood cell formation. This designation establishes its role as a fundamental therapeutic intervention rather than a general dietary supplement.


Composition and Form: A Stabilized Parenteral Solution

  • The formulation centers on the active ingredient Cyanocobalamin, provided as an aqueous solution for injection typically supplied in glass ampoules. Cyanocobalamin is a synthetic derivative of cobalamin, specifically chosen for its stability in pharmaceutical preparations. The solution is designed for parenteral administration via intramuscular (IM) injection, which is a key differentiating feature that bypasses potential absorption issues. This single-entity product is often employed in situations where guaranteed systemic delivery of the nutrient is required.

What is the General Purpose of Depovit B12?

The general purpose of Depovit B12 is to serve as an essential co-factor required for two vital physiological processes: red blood cell production and crucial nervous system maintenance. By supplying the body with Cyanocobalamin, the preparation helps facilitate the necessary DNA synthesis for the maturation of red blood cells (erythropoiesis) and aids in maintaining the structural integrity of nerve tissue. Vitamin B12 injections are classified as a core medical treatment for nutritional deficits.

Regulatory References

  1. World Health Organization
Advertisements

What side effects are possible with Depovit B12?

Possible Side Effects and Safety Information for Depovit B12

The official safety profile for Cyanocobalamin injection (Depovit B12) primarily documents potential adverse reactions grouped by the physiological system affected and their associated frequency, as classified by regulatory agencies.

Adverse reactions are broadly categorized, with serious systemic events being classified as rare. These rare, though clinically significant, reactions include severe hypersensitivity reactions such as anaphylactic shock and, less commonly, peripheral vascular thrombosis.

Less serious, non-systemic effects are observed in several areas. Dermatological reactions may occur, encompassing issues like generalized itching, rash (transitory exanthema), and acneiform eruptions. Gastrointestinal effects, such as mild transient diarrhea, may also be noted.


Serious Safety Constraints and Contextual Notes

Official labeling defines specific constraints and requirements for use:

  • Contraindications: Cyanocobalamin injection is strictly contraindicated in individuals with a known allergy to cobalt or to the active substance itself. It is also contraindicated in patients diagnosed with early Leber's Disease (hereditary optic nerve atrophy), as administration is associated with causing severe optic atrophy.
  • Early Treatment Monitoring: In cases involving the intensive treatment of severe megaloblastic anemia, there is a documented risk of hypokalemia (low potassium), which may require close monitoring of serum potassium levels, particularly early in therapy. Furthermore, pulmonary edema and congestive heart failure have been noted to occur early in the treatment of severe anemia.

This framework ensures that risks are managed based on documented frequency, severity, and specific patient conditions, such as hereditary disorders or compromised kidney function.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official Regulatory Statements on Overdose

Official labeling for injectable Vitamin B12 (Cyanocobalamin), which is the active substance in Depovit B12, reports rare but serious adverse events associated with its administration. These events define the regulatory overdose profile and include documented occurrences of anaphylactic shock and death.

Clinical Manifestations and Risk Factors

While some regulatory documents state that no specific overdosage has been reported, high doses and rapid parenteral (injectable) administration have been associated with severe reactions. These documented clinical manifestations may include pulmonary edema, congestive heart failure early in treatment, and peripheral vascular thrombosis.

Specific patient risks are noted in regulatory warnings. In patients with severe megaloblastic anemia undergoing intense treatment, there is a risk of developing hypokalemia and potentially sudden death. Patients with early Leber's disease (hereditary optic nerve atrophy) treated with cyanocobalamin have experienced severe and rapid optic atrophy.

Required Emergency Actions

Immediate medical attention is required if a person takes more than the prescribed amount. Official instructions state to talk to a doctor or go to the hospital straight away in this circumstance. An intradermal test dose may be recommended before administration of the injection for patients suspected of sensitivity to the drug.

Advertisements

Therapeutic Uses of Depovit B12

What Depovit B12 Treats: Main Uses and Benefits

Depovit B12 injection is a relevant therapeutic intervention used to manage the profound systemic consequences of severe Vitamin B12 deficiency, primarily when absorption from the gut is impaired. The injection is commonly used to address B12 lack caused by conditions like Pernicious Anemia and other malabsorption issues. The treatment is commonly used for symptomatic management across the haematological and neurological systems.

The medication is typically applied in addressing conditions characterized by periods of heightened symptoms, including Megaloblastic Anemia, peripheral neuropathy, and deficiency states resulting from gastrectomy or Crohn's Disease. It is relevant for easing symptoms that interfere with daily comfort, such as extreme fatigue, weakness, numbness, tingling, and mental confusion. The core benefit contributes to supporting functional nerve health and supports the maintenance of red blood cell production.

The treatment aims to provide supportive therapeutic benefit, especially in chronic conditions where parenteral delivery of the vitamin is considered relevant for functional stability.


Quick Fact: Support for Deficiency Symptoms

Domain Conditions Used For Primary Benefit
Haematology Megaloblastic Anemia, Pernicious Anemia May assist with managing extreme fatigue and weakness.
Neurology Peripheral Neuropathy, Confusion Supports functional nerve health and supports the easing of sensory distress.
Context Malabsorption Syndromes Assists with long-term therapeutic support to manage recurrence.

Regulatory References

  1. NIH MedlinePlus overview on Cyanocobalamin Injection
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Depovit B12 (Cyanocobalamin injection) is intended for populations with confirmed Vitamin B12 deficiency due to malabsorption, such as those with Pernicious Anemia or post-surgical syndromes. Regulatory authorities define strict boundaries for its use:

  • Contraindicated Populations: The medicine must not be used in patients with a history of hypersensitivity or allergy to Vitamin B12 or cobalt. It is also contraindicated in patients with early Leber's disease (hereditary optic nerve atrophy) due to the risk of severe optic nerve damage.

  • Age-Related Restrictions: Use is not recommended for neonates and infants because some injectable formulations contain Benzyl Alcohol, a preservative associated with a specific toxicity risk in this age group.

  • Conditional Restrictions: Patients with impaired kidney function should use the medicine with caution, as prolonged parenteral administration may lead to aluminum accumulation. Close patient monitoring, particularly of serum potassium, is required during the initial, intensive treatment of severe megaloblastic anemia.

  • Maternal Use Status: The medicine holds an FDA Pregnancy Category C status, meaning use is permitted only if the potential benefit justifies the potential risk. The vitamin is excreted in human milk, and adverse effects on a nursing infant are not typically anticipated.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents detail specific interaction patterns for Cyanocobalamin injection, focusing on effects that modify its therapeutic response or plasma concentration. The interaction profile is defined by pharmacodynamic antagonism and constraints related to the simultaneous use of certain substances.


Documented Pharmacodynamic and Exposure Interactions

Interacting Substance Official Regulatory Description Interaction Classification
Chloramphenicol Co-administration may antagonize the hematopoietic response to Vitamin B12, interfering with red blood cell production. Pharmacodynamic Antagonism
Oral Contraceptives Concurrent administration may cause a decrease in the serum concentration of Vitamin B12. Reduced Exposure

Substance and Timing Constraints

Regulatory information specifies constraints related to other substances:

  • Vitamin C (Ascorbic Acid): Large amounts of Vitamin C may destroy Cyanocobalamin. Therefore, patients should avoid ingesting large amounts of Vitamin C within one hour of oral B12 administration; this rule applies where B12 is absorbed through the gut.
  • Heavy Alcohol Intake: Chronic, heavy consumption of alcohol (for more than two weeks) may impair the overall absorption of Vitamin B12.

Furthermore, for patients with impaired kidney function, a caution is noted: due to aluminum content in the product, there is a potential for aluminum to reach toxic levels with prolonged parenteral administration. This is a material interaction caution specific to the product composition in this population.

Advertisements

Mechanism of Action

Enzyme-Dependent Action on DNA and Cell Maturation

The mechanism of Depovit B12 (Hydroxocobalamin) is centered on its function as an essential enzyme cofactor required to sustain two critical metabolic pathways. The first domain involves the conversion into Methylcobalamin, which is necessary for the activation of the Methionine Synthase enzyme. This action is critical for regenerating active folate (Tetrahydrofolate, THF), which permits the synthesis of DNA building blocks required for cellular replication and maturation in rapidly dividing tissue like bone marrow.

Regulation of Mitochondrial Metabolism and Nerve Structure

The second distinct domain involves conversion to Adenosylcobalamin, a cofactor required by the mitochondrial enzyme Methylmalonyl-CoA Mutase. This mechanism is essential for regulating metabolic flow and facilitating the conversion of neurotoxic methylmalonic acid (, MMA,) precursors. This molecular conversion contributes to maintaining the structural and functional integrity of nerve axons and their myelin sheaths.

Advertisements

Dosage and Administration Information

How Depovit B12 Is Used

The administration of Depovit B12 (Cyanocobalamin injection) follows standardized procedural guidelines. The general principle of use is a two-phase parenteral regimen designed to bypass intestinal malabsorption issues.


Official Routes and Administration

The injectable solution is administered via intramuscular (IM) injection or by deep subcutaneous (SC) injection. The medication is not intended for the intravenous (IV) route, as IV administration is avoided due to the rapid urinary loss of the vitamin. The solution, often supplied at a standard strength of 1,000 micrograms (mcg) per milliliter (mL), should be administered by or under the direct supervision of a trained healthcare professional.


Standard Dosing Regimens

Therapy typically begins with an initial intensive course followed by a chronic maintenance schedule. The dosage and frequency vary slightly between jurisdictions but adhere to the two-phase model.

Context Initial/Loading Phase (Adults) Maintenance Phase (Adults)
Pernicious Anemia (General) 100 mcg daily IM or SC for 6 to 7 days, or 1,000 mcg on alternate days. 100 mcg to 1,000 mcg monthly IM for long-term therapy.
Pediatric Dosing Daily doses between 0.5 and 3 mcg are specified for nutritional deficiency states. Not applicable; long-term therapy is adjusted to clinical need.

Procedural Context and Duration

For improved patient comfort, the solution may be warmed to body temperature prior to injection. The duration of use is defined by the underlying condition; for irreversible malabsorption conditions like pernicious anemia, life-long monthly maintenance therapy is required.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Depovit B12

Evidence for use in Pernicious Anemia

The use of injectable B12 was studied for managing Pernicious Anemia, a condition linked to a lack of intrinsic factor needed for absorption. The core evidence base includes foundational historical cohort studies and older comparative trials. Research explored outcomes related to systemic imbalance, specifically tracking changes in blood markers and symptoms in adult populations.

Studies monitored how symptoms evolved in the observed populations, describing patterns observed in blood cell composition and size following the start of therapy. Findings indicate patterns related to B12 level changes. Studies monitored how changes in B12 status corresponded with the symptoms reported by participants over an initial period.

Certainty remains low regarding specific aspects, as few modern controlled studies exist, and evidence relies heavily on historical reports. Furthermore, optimal long-term effects are not fully established.


Evidence for use in Correcting Megaloblastic Anemia

Injectable B12 was evaluated in research exploring short-term changes for correcting Megaloblastic Anemia due to B12 deficiency. Comparative trials and observational studies explored how the injection was associated with changes in red blood cell production markers and metabolic markers in both adult and pediatric populations.

Findings describe patterns observed in the studies, showing shifts in blood cell indices toward established reference ranges. Research describes how the treatment was studied for metabolic markers linked to the deficiency. Evidence is limited by the fact that sample sizes were modest across many trials, and there is limited information for long-term outcomes regarding ideal maintenance frequency.


Evidence for Managing Neurological Symptoms

Research examined the injection's role in addressing the neurological symptoms associated with severe B12 deficiency. The evidence largely stems from observational cohort studies and systematic reviews of smaller trials. Studies monitored outcomes related to physical discomfort and changes in nerve function measures.

Studies report how symptoms evolved, describing a pattern of stabilization or gradual change in measured neurological functions. Findings were mixed regarding the full potential for recovery, which may be related to the length and severity of the deficiency before treatment began.


What Remains Uncertain About Depovit B12 Research

This section highlights areas where the evidence base is incomplete. For some long-standing indications, comparative evidence is lacking because modern, placebo-controlled trials may be considered unnecessary. Long-term effects are not fully established for all outcomes, particularly concerning potential recovery from chronic neurological damage, where data are still emerging. Overall, the evidence highlights what is known—and what is still uncertain—emphasizing that research provides context but not individual predictions.

Key Studies & References

  1. Vitamin B12 (Cyanocobalamin) Injection: MedlinePlus Drug Information
  2. Model List of Essential Medicines (relevant section on antianemics/vitamins)
  3. Vitamin B12 deficiency and neurological complications: a systematic review (relevant to neurological outcome studies)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Depovit B12 (FAQ)


Q: What is the difference between Depovit B12 and other B12 injections?

Depovit B12 contains the active ingredient Cyanocobalamin, which is a synthetic form of Vitamin B12. Once the injection is administered, the body converts Cyanocobalamin into the two biologically active forms required for cellular function. Other injectable products may contain one of these active forms directly, such as methylcobalamin.


Q: Can Depovit B12 affect sleep patterns?

Official information generally describes potential side effects such as headache and dizziness, or feeling unusually weak or tired. The product's official regulatory labeling does not commonly list specific effects on sleep patterns, such as insomnia or drowsiness, among the documented side effects.


Q: Can someone take multivitamins while using Depovit B12?

Regulatory documents list a potential interaction with large amounts of Vitamin C (Ascorbic Acid), which may interfere with B12. Because multivitamins contain various ingredients, patients may review the specific ingredients and total amounts of multivitamins, as avoiding large doses of potentially interfering substances is noted in labeling.


Q: Can Depovit B12 interact with medications used for stomach acid reduction?

While Depovit B12 is an injection that bypasses the digestive system, official sources note that the long-term use of chronic acid-reducing medication can be a cause of B12 deficiency. The drug is approved to address B12 deficiency, which is often linked to malabsorption issues.


Q: Can the use of Depovit B12 affect lab test results?

Yes, official regulatory documents indicate that the use of Depovit B12 may invalidate diagnostic blood assays for folic acid and Vitamin B12. To ensure accurate results, official documents indicate that specific timing of blood tests may be necessary relative to administration.


Q: Is Depovit B12 safe for people with a history of heart problems?

Adverse events related to the heart, such as pulmonary edema (fluid in the lungs) and congestive heart failure, have been reported early in the intensive treatment of severe anemia. Patients with a history of heart issues are typically advised to disclose this information to their healthcare provider.


Q: Is Depovit B12 meant for short-term or long-term use?

The duration of treatment is entirely based on the underlying health condition. For irreversible malabsorption issues, such as pernicious anemia, official regulatory documents indicate that life-long monthly maintenance therapy is typically required.


Q: Is Depovit B12 used for things other than B12 deficiency?

The medicine's official purpose is to address Vitamin B12 deficiency caused by conditions like malabsorption. Official product information notes that it may also be used in diagnostic tests or to treat specific rare, inherited metabolic conditions.


Q: Can Depovit B12 be given to teenagers or children?

Official labeling addresses the use of the medicine in children for nutritional deficiency states. However, injectable formulations containing the preservative Benzyl Alcohol are generally not recommended for neonates and infants due to a specific associated toxicity risk.


Q: Do any foods need to be avoided while taking Depovit B12?

For the injectable form of B12, official regulatory documents generally state there are no known interactions with general foods or drinks that must be strictly avoided. Interactions are typically focused on other medications or substances like high-dose Vitamin C.


Q: How long does the B12 from Depovit B12 typically stay in the body?

Official documents on the drug's action state that the major portion of the injected dose is excreted in the urine within the first eight hours of administration. A large percentage continues to be eliminated in the urine over the first 48 hours.


Q: Can people with kidney or liver conditions use Depovit B12?

Use requires caution for patients with impaired kidney function. Due to the presence of aluminum in the preparation, there is a potential for accumulation to toxic levels with prolonged use in this population. Liver conditions are not typically noted with the same specific caution.


Q: Is Depovit B12 used to treat nerve damage (neuropathy)?

The general purpose of the drug is to aid in the maintenance of the nervous system and address the neurological symptoms associated with severe Vitamin B12 deficiency. Research has examined its role in addressing these symptoms, which can include nerve damage.


Q: Can Depovit B12 be used for general 'wellness' or preventative health?

The product is officially approved for the treatment and prevention of B12 deficiency in patients with confirmed need, particularly those with malabsorption issues. Its role is defined by addressing established nutritional deficits rather than general wellness.


Q: Are there any known interactions between Depovit B12 and alcohol?

Official regulatory documents indicate that heavy alcohol intake for longer than two weeks may impair the absorption of B12 from the gut. However, there are no known interactions widely described between heavy alcohol intake and the injectable form itself.


Q: Are there restrictions on driving or operating machinery after a Depovit B12 dose?

Official documents generally advise caution regarding activities like driving or operating machinery if the patient experiences side effects such as dizziness or feeling weak.


Q: What is the active form of Vitamin B12 in Depovit B12?

The active ingredient in the injection is Cyanocobalamin. Once administered, the body converts this synthetic form into the biologically active coenzyme forms, Methylcobalamin and Adenosylcobalamin, which are required for critical cellular processes.


Q: Are there specific symptoms that indicate a person may need Depovit B12?

The drug is used to treat conditions that cause B12 deficiency. If the deficiency is left unaddressed, it may be associated with symptoms like anemia and, in severe cases, progressive degenerative lesions of the spinal cord.


Advertisements

How should Depovit B12 be stored and disposed of?

Official Storage and Disposal Requirements

Storage Component Requirement
Temperature Store at or below 25 C (77 F). Do not freeze or store above the maximum stated temperature.
Light Protection Keep the ampoules in the original outer carton to protect the medicine from light.
Child Safety Store the medicine securely out of the sight and reach of children.
Stability Do not use the product after the expiry date. The solution is for single use only; discard any remaining portion.
Disposal Do not dispose of unused or expired Depovit B12 via household waste or wastewater.
Sharps Place used syringes and needles immediately into a puncture-proof sharps container.

Official regulatory information mandates these conditions to ensure product stability and safety. Unused or expired medicine should be returned to a pharmacy or designated collection point to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Depovit B12 found in:

A-Z Index: